Bispecific antibody and application thereof

A bispecific antibody, binding activity technology, applied in the field of tumor therapy and molecular immunology, can solve the problems of low binding activity and low tumor cell killing activity
CN110669135AActive Publication Date: 2020-01-10L&L BIOPHARMA CO LTD
12 Cites 7 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
L&L BIOPHARMA CO LTD
Publication Date
2020-01-10

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a bispecific antibody and an application thereof. Wherein the bispecific antibody comprises a first protein functional area and a second protein functional area; wherein the first protein functional area is the protein functional area targeting TIM-3; the TIM-3 full-length antibody of the targeting TIM-3 corresponding to the first protein functional area has weak binding activity with macaca TIM-3, has strong binding activity with marmoset and human TIM-3, and can activate the killing effect of human NK cells on tumor cells. The bispecific antibody not only can retain the activity of activating PBMC (NK) to kill tumor cells of the single TIM-3 antibody, but also can retain the original activity of the other protein functional area, and can achieve the activity equivalent to or better than the activity of activating T lymphocytes by combining two molecules (synergistic effect). The bispecific antibody (e.g., LB141) of the present invention has a more excellent effect in therapy than PD-1 antibody treatment alone or combined use of the TIM-3 antibody and the PD-1 antibody.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the fields of tumor therapy and molecular immunology, and specifically relates to a bispecific antibody comprising two protein functional regions, wherein one protein functional region is a protein functional region targeting TIM-3. Background technique

[0002] Tumor immunotherapy is a major breakthrough in the field of tumor treatment in recent years. In recent years, the research on the immune checkpoint PD-1 / PD-L1 has been extremely hot. In the past less than a year, 5 PD-1 antibody drugs have been launched in China. Among immune checkpoints other than PD-1 / PD-L1, T cell immunoglobulin domain and mucin domain 3 (TIM-3) is an immune system that may cooperate with PD-1 / PD-L1 to regulate T cell activity. One of the checkpoint molecules. TIM-3 is a transmembrane receptor protein expressed on IFN-γ-secreting Th1 (T helper 1) CD4+ cells and cytotoxic CD8+ T (Tc1) cells. In addition to the expression of Th1 and Tc1 that secrete...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More